

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Haohai Biological Technology Co., Ltd.*

上海昊海生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6826)

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The amendments to the articles of association (the “**Articles of Association**”) of Shanghai Haohai Biological Technology Co., Ltd.* (the “**Company**”) was approved by the meeting of the board of directors of the Company (the “**Board**”) held on 16 August 2024. The Board was authorized to approve the amendments to the Articles of Association pursuant to the 2021 Restricted A Share Incentive Scheme (as defined below) and 2023 Repurchase Mandate (as defined below).

This announcement is made by the Company pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

References are made to the Company’s 2021 restricted A share incentive scheme (the “**2021 Restricted A Share Incentive Scheme**”) approved and adopted by its shareholders at the 2022 extraordinary general meeting, the 2022 first A shareholders’ class meeting and the 2022 first H shareholders’ class meeting held on 7 March 2022; and the Company’s resolutions regarding the granting of a general mandate to the Board to repurchase H shares of the Company (the “**H Shares**”) approved at the Company’s 2022 annual general meeting, the 2023 first A shareholders’ class meeting and the 2023 first H shareholders’ class meeting convened on 12 June 2023 (the “**2023 Repurchase Mandate**”).

Pursuant to the 2021 Restricted A Share Incentive Scheme, the Company issued 526,445 A Shares on 26 March 2024. Pursuant to the 2023 Repurchase Mandate, the Company repurchased a total of 3,296,500 H Shares during the period from 25 August 2023 to 20 December 2023 and cancelled such repurchased H Shares on 19 March 2024.

Upon completion of the above-mentioned share issuance and cancellation of all of repurchased H Shares, the total share capital of the Company was changed from 171,477,258 shares to 168,707,203 shares, and the registered capital of the Company was changed from RMB171,477,258 to RMB168,707,203. At the meeting of the Board held on 16 August 2024, the Board considered and approved the proposal to change the registered capital of the Company and amend the Articles of Association in accordance with such changes in the total share capital and registered capital of the Company. The amendments to the Articles of Association are as follows:

No.	Existing Articles	Revised Articles
1	<p>Article 18</p> <p>Upon establishment of the Company, as approved by the securities regulatory authorities under the State Council and the Hong Kong Stock Exchange, the Company issued 40,045,300 ordinary shares through initial public offering, all are H shares. Upon completion of the aforesaid issue of H shares, the capital structure of the Company: total share capital is 160,045,300 shares, of which 120,000,000 are A shares, representing 74.979% of ordinary share capital of the Company, and 40,045,300 are H shares, representing 25.021% of ordinary share capital of the Company.</p> <p>.....</p> <p>The current total number of shares of the Company is 171,477,258, of which 138,582,158 are A shares, representing 80.817 % of ordinary share capital of the Company, and 32,895,100 are H shares, representing 19.183% of ordinary share capital of the Company.</p>	<p>Article 18</p> <p>Upon establishment of the Company, as approved by the securities regulatory authorities under the State Council and the Hong Kong Stock Exchange, the Company issued 40,045,300 ordinary shares through initial public offering, all are H shares. Upon completion of the aforesaid issue of H shares, the capital structure of the Company: total share capital is 160,045,300 shares, of which 120,000,000 are A shares, representing 74.979% of ordinary share capital of the Company, and 40,045,300 are H shares, representing 25.021% of ordinary share capital of the Company.</p> <p>.....</p> <p>The current total number of shares of the Company is <u>168,707,203</u>, of which <u>139,108,603</u> are A shares, representing <u>82.456%</u> of ordinary share capital of the Company, and <u>29,598,600</u> are H shares, representing <u>17.544%</u> of ordinary share capital of the Company.</p>
2	<p>Article 19</p> <p>The registered capital of the Company is RMB171,477,258.</p>	<p>Article 19</p> <p>The registered capital of the Company is RMB<u>168,707,203</u>.</p>

Save for the above amendments to the Articles of Association, other provisions of the Articles of Association remain unchanged.

The Board was authorized under the 2021 Restricted A Share Incentive Scheme to handle all matters necessary for the vesting of shares, among which including changing the registered capital, making corresponding amendments to the Articles of Association in respect of total share capital and shareholding structure, etc., and fulfilling the statutory registration and filing procedures. The Board was also authorized by the 2023 Repurchase Mandate to carry out cancellation procedures for the repurchased shares, reduce registered capital, make corresponding amendments to the Articles of Association in respect of the changes in the total share capital and shareholding structure, etc., and to carry out relevant statutory registrations and filing procedures within and outside of the People's Republic of China. In view of the above, these amendments to the Articles of Association will not be submitted for consideration and approval at the general meeting of the Company, and shall become effective on 16 August 2024.

The English version of the above amendments to the Articles of Association is an unofficial translation of its Chinese version. In case of any discrepancies, the Chinese version shall prevail.

By order of the Board
Shanghai Haohai Biological Technology Co., Ltd.*
Chairman
Hou Yongtai

Shanghai, the PRC, 16 August 2024

As at the date of this announcement, the executive directors of the Company are Dr. Hou Yongtai, Mr. Wu Jianying, Ms. Chen Yiyi and Mr. Tang Minjie; the non-executive directors of the Company are Ms. You Jie and Mr. Huang Ming; and the independent non-executive directors of the Company are Mr. Shen Hongbo, Mr. Jiang Zhihong, Mr. Su Zhi, Mr. Yang Yushe and Mr. Zhao Lei.

* *For identification purpose only*